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Abstract
Cancer  has  been  for  many  years  the  second leading  cause  of  mortality  right  after
cardiovascular  diseases,  representing  25%  of  all  the  deaths  reported  yearly  and  this
tendency is expected to increase. Although the recent public health emergency caused by
COVID-19 pandemic diverted much of the attention of policy makers, the public opinion
and even researchers  from other  important,  economical  relevant  and deadly  diseases,
cancer  still  remains  as  one  of  the  major  healthcare  issues.  Moreover,  recent  studies
revealed the negative effects of COVID-19 pandemic on the increase of avoidable cancer-
related deaths.  It  is  then the perfect  time to bring back the spotlight  onto the topic of
cancer.
The aim of this paper is to share the outcomes of the workshop organized by the COST
(European Cooperation in Science and Technology) Association, bringing together sixty
participants representing a broad variety of stakeholders, to discuss a holistic approach on
how to beat cancer by 2030.
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The conclusions of this workshop are highly relevant for the community and are supporting
the work being undertaken by the EU Mission Board on Cancer. This report lays down the
main conclusions and recommendations agreed by the workshop participants, focusing on
different  aspects  such as better  stakeholder  collaboration,  citizen education,  innovative
therapies, and patient-centric care.
Keywords
Cancer Prevention and Treatment, Science Policy, Research Roadmap
Date and place
21st to 22nd May 2019, COST Association, Av. Louise 149, 1050 Brussels, Belgium
Contributions
The conclusions and recomendations of this paper are the result of the discussions and
ideas  from  all  the  workshop  participants  (full  list  in  supp  material  1:  Booklet  of  the
Workshop - Beating cancer by 2030: mission impossible?).
Disclaimer:  Dr  Wolfgang  Burtscher,  Deputy  Director  General  at  DG  Research  and
Innovation (EC) and Dr Sanja Damjanovic, Minister for Science in Montenegro, attended
the workshop as invited guests and gave presentations for the benefit of the participants.
They were not active participants and therefore, the conclusions and recommendations
reported in this paper shall  not be associated with their opinion nor the position of the
institutions they represented.
Description, Agenda and Participants
See  Suppl.  material  1  -  Booklet  of  the  Workshop  -  Beating  cancer  by  2030:  mission
impossible?
Opening Remarks
The  recent  COVID-19  pandemic  overshadowed  the  importance  of  other  major  health
issues such as cancer (Sarpless 2020). Although the importance on investing resources in
the fight against COVID-19 is recognised, cancer is still a deadly and economically relevant
disease. Moreover, recent studies have highlighted the negative effects of the COVID-19
pandemic on the increase of avoidable deaths in four major tumours (Maringe 2020) and
experts have shown the need to prioritizing the various aspects of cancer care to mitigate
these negative effects in the management of cancer patients (Curigliano 2020) .
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The COST Association organised a COST Connect event entitled “Beating cancer by 2030:
mission impossible?”.  This  paper  shares the conclusions and recommendations of  this
event to help refocus attention to this important issue.
Introduction
In 2015, cancer caused around 1.320.000 deaths in the European Union (EU), constituting
the second leading cause of mortality second only to cardiovascular diseases, representing
25% of all the deaths reported (OECD and European Union 2018).
Considering  the  worldwide,  exponential  population  increase  and  the  average  life
expectancy, cancer is now identified as one of the major causes of death (first or second
leading  cause  of  death  before  70  years  of  age  in  91  countries).  Noteworthy,  cancer
currently accounts for 20% of all deaths occurring in Europe every year (3.9 million new
cases and 1.9 million deaths yearly), and is expected to stand out as the major leading
cause of death worldwide during this century (Bray 2018). The deadliest cancers in Europe
are those affecting lung, liver, stomach, breast and colorectal tissue. Analysing the pan-
European average 5-year survival statistics, males diagnosed with cancer in the age 45-54
have almost  one-third  less  chance of  survival  (average 50.22%) compared to  females
(average 74.06%). This discrepancy however is reduced significantly in males and females
diagnosed  in  the  age  range  65-74  (52.06  and  55.76  %  respectively)  and  almost  no
differences  are  observed  in  people  with  more  than  75  years  (41.96  and  41.04  %
respectively) (European Commission/JRC. Data Explorer. Estimates of survival, by country
and cancer site).
The main preventable causes of cancer in Europe reside in unhealthy lifestyles,  which
include excessive alcohol consumption, tobacco use, inappropriate diet, obesity, and lack
of physical activity. In fact, as a result of the westernization of the lifestyle, changes in the
profile of the most common cancer types are more striking in emerging economies, where
a displacement of  infection-related and poverty-related cancers by those cancers more
frequently reported in developed countries is taking place (Bray and Soerjomataram 2015,
Maule  and  Merletti  2012).  The  difference  of  cancer  profiles  between  regions  remains
crystal  clear,  highlighting  the  geographic  diversity  and  the  persistence  of  specific  risk
factors according to the different phases of socio-economic transition.
The economical sustainability of cancer management in national health systems remains a
major concern. Paralleling the epidemiological cancer data, the costs of cancer care are
increasing, likely as a result of the development of new diagnostic imaging techniques and
new innovative therapies. Importantly, in European countries, up to 30% of total hospital
expenditure arises directly from oncology-related expenses and the costs spent on new
drugs  which  is  exponentially  rising  is  expected  to  continue  increase  (Pramesh  2015,
Luengo-Fernandez 2013). Between 1995 and 2014, estimated cancer-related expenditure
in the EU increased 133% (from €35.7 billion to €83.2 billion, respectively) (Jönsson 2016).
However, these values might be underestimated since cancer costs in EU were reported to
reach €126 billion in 2009. It is noteworthy that approximately 40% of these expenses (€51
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billion)  were  related  with  health  care  costs,  while  productivity  losses  because of  early
death, lost working days and informal care represented a cost of €42.6 and €9.43 and
€21.3 billion, respectively (Luengo-Fernandez 2013). Across the EU member states, a high
discrepancy is observed regarding health care costs (average cost of €102 per person),
ranging from € 16 per person (Bulgaria) to €184 per person (Luxembourg). Although such
differences  are  observed,  the  costs  related  with  non-pharmacological  management  of
cancer are stable whilst cancer drugs are known to markedly contribute for the increased
costs experienced in cancer management. Overall,  despite all  the differences in cancer
therapeutics among the EU members, burdening health systems with all these fast-growing
costs is unsustainable and if the trends continue in this direction, cancer care might be
significantly compromised in the future.
All this data reinforces the need for strong efforts in European cancer research to invest
money, create infrastructures, and distribute knowledge with the final goal to beat cancer
by 2030. In this regard, the European Cooperation in Science and Technology (COST -
www.cost.eu), an EU-funded programme, enables researchers and innovators to set up
COST Actions, interdisciplinary research networks in Europe and beyond to timely address
scientific and societal challenges. COST also organises highly interactive COST Connect
events aiming at bringing together representatives of the funded networks with the wider
scientific communities, stakeholders and policymakers working together. Such events aim
at creating  synergies  and reducing research fragmentation  in  the  field,  initiating  future
research  cooperation.  They  actively  promote  the  COST  Actions  strategic  research
roadmaps, identify new funding opportunities and priorities for Horizon Europe.
The aim of this paper is to share the outcomes of the workshop organized under the COST
Connect series on cancer research: “Beating cancer by 2030”. This workshop provided a
multidisciplinary platform where researchers, policy-makers, cancer patient organisations
and  industry  discussed  the  challenges  in  cancer  research,  aiming  at  an  improved
coordination at European level. The event and this report come at a crucial time, providing
pan-European input into the ongoing Horizon Europe discussions, as cancer has been
identified as one of the future missions in the next Framework Programme for Research
and Innovation.
Methods
The methodology of the workshop is based on the concept of the Pro-Action Café, which is
an interactive yet simple facilitation methodology for creative, inspirational, and relevant
conversations.
The event has no set agenda and starts with short “setting-the-scene” presentations aiming
at providing a general overview of the challenges and activities of the different actors in the
field. In a Pro-Action Café, discussion topics are proposed by the participants themselves
and selected by the audience, ensuring a maximum engagement and relevant outcomes.
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After  agreement  of  the  discussion  topics,  participants  invite  the  audience  to  define
strategies to overcome a specific identified challenge. This is achieved by three rounds of
conversation in café style, each guided by a few generic questions to help deepen and
focus the conversations. In each round, a new set of participants join the tables, benefiting
from the collective intelligence present during the event.
Structure of the workshop
The  detailed  program  of  the  workshop  is  given  in  Suppl.  material  1.  Booklet  of  the
Workshop - Beating cancer by 2030: mission impossible?
The  workshop  focused  on  possible  strategies  to  beat  cancer.  The discussions  were
supported by presentations from policy makers who presented the current state of affairs in
the policy arena (Fig. 1). During the workshop short presentations from stakeholders and
COST  Actions’  representatives  were  also  given  to  support  framing  and  fostering  the
discussions (Fig. 2).
From the Stakeholder side presentations focused on their activities in the field: Dr Manola
Bettio presented ECIS - European Cancer Information System from the Joint Research
Centre (EC); Dr Chrissie Brierley presented the view of the JPI Healthy Diet for a Healthy
Life. Industry initiatives were presented by Dr Alexandre Ceccaldi (European Technology
 
Figure 1.  
Dr Wolfgang Burtscher,  Deputy Director General  at  DG Research and Innovation (EC) (L)
opened the  event  presenting  an  overview of  the  state  of  play  of  current  Horizon Europe
negotiations and the planned Mission in the field of Cancer. Dr Sanja Damjanovic, Minister for
Science in Montenegro (R), presented the roadmap for establishing The South East European
International Institute for Sustainable Technologies (SEEIIST), which aims developing Hadron
Cancer Therapy and Biomedical Research with Protons and Heavy Ions.
 
Beating Cancer by 2030: Mission Impossible? 5
Platform on Nanomedicine). The views of the patients were presented by Ms Antonella
Cardone (European Cancer Patient Coalition).  The need and potential  for data sharing
services was presented by Dr Ashley Woolmore (IQVIA - CODE).
Representatives of selected COST Actions presented the achievements of the different
networks  in  different  aspects  of  cancer  research:  Dr  Christof  Krafft  on  Raman-based
applications  for  clinical  diagnostics  (Raman4clinics;  BM1401);  Dr  Daniel  Ortega:  on
Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy
(RADIOMAG; TD1402);  Prof.  Sven  Brandau  on  European  Network  of  Investigators
Triggering Exploratory Research on Myeloid Regulatory Cells (Mye-EUNITER; BM1404);
Prof. Stefano Alcaro on Multi-target paradigm for innovative ligand identification in the drug
discovery process (MuTaLig; CA15135); Dr Georgia Pennarossa on In vitro 3-D total cell
guidance and fitness (CellFit;  CA16119);  Dr  Puri  Fortes on Delivery of  Antisense RNA
Therapeutics  (DARTER,  CA17103);  Dr  Richarda  De  Voer  on  Identifying  Biomarkers
Through  Translational  Research  for  Prevention  and  Stratification  of  Colorectal  Cancer
(TRANSCOLONCAN; CA17118).
The workshop participants agreed to focus on some important topics which were discussed
among them following a Pro-Action Café methodology (Fig. 3).
The conclusions  and recommendations  presented in  this  paper  are  the  result  of  such
discussions on the following topics:
I. Translational research and precision medicine: How to improve translational cancer
research? How to make precision medicine real in diagnosis and treatment?
 
Figure 2.  
COST  Actions  representatives  and  Stakeholders  short  presentations  on  their  activities  in
Beating Cancer.
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II.  Cancer prevention:  How to achieve widespread healthy lifestyle choices for cancer
prevention and survival?
III. Patients: How to evaluate the quality of cancer care that patients and their carers are
receiving across Europe?
IV. Low-hanging fruits: How to improve cancer treatment approaches in cancers with the
most urgent needs by 2030?
V. Strategy: How can we build a process to crosstalk and coordinate between the different
stakeholders (academia, patients, industry, healthcare providers) in the field of cancer to
get the most value for maximising efficacy and beating cancer?
Key outcomes and discussions
I.  Translational  research  and  precision  medicine:  How  to  improve  translational
cancer research? How to make precision medicine real in diagnosis and treatment?
Moving novel cancer targets from bench to bedside is always a priority but also a big
challenge; the translation efficiency and speed depends on multiple factors such as the
ability  to  prioritize  targets  and  accelerate  their  validation,  the  presence  of  solid
infrastructures to link basic and clinical science, the ability to create academic spin-offs and
a  solid  collaboration  pipeline  with  pharmaceutical  companies.  So,  what  is  missing  to
 
Figure 3.  
Participants discussing in small groups during the Pro-Action Café.
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improve research translation in  Europe? The working group identified several  potential
action points, summarized here below:
1. Improvement of pre-clinical studies quality:  the failure rate of clinical trials is
high (Fogel 2018). A major reason for this is the poor pre-clinical validation of the
cancer  targets;  mainly  because  cell  lines  or  the  animal  models  used  are  not
predictive  on what  will  happen in  the  clinical  context.  We need to  invest  more
resources to develop better pre-clinical cancer models which allow basic scientists
to select more rigorously their targets and will improve success rates in the clinical
context.
2. Access to translational grants: one of the biggest hurdles for an academic lab
willing to move its targets into an industrial setting, such as an academic start-up, is
to find sufficient funds to further validate the targets and the platform in order to get
Venture or Angel capital seed investments; there is the need to increase enterprise
funds for academic labs.
3. Initiation of a European Translational Forum (ETF) that can be developed into
a European Translational Network (ETN): two key hurdles that hinder rapid and
successful translation of research findings are the difficulty to form efficient larger
teams and consortia to execute the translational research and the difficulty for such
consortia to obtain initial funding in a reasonable time frame. An innovative funding
and  networking  format,  termed  ETF,  could  overcome  this.  ETF  would  be  a
networking event/conference, which is associated with a dedicated budget. During
the ETF translational consortia must be formed to be eligible for the funding call.
After the ETF consortia formed during the event (and only those) have the chance
to apply for the translational grants. It is anticipated that such an initiative would be
highly attractive for those study groups interested in direct translational research.
The aim of this network would be to give basic and clinical scientists, stakeholders,
and regulatory entities a platform, with a budget, to access to grants specifically
designed to  move a  specific  project  from pre-clinical  to  clinical  validation.  This
network would allow the comparison of relevant targets for drug development, to
gain access to technology and standardization platforms, to create a centralized
interpretation of clinically actionable variants.
II.  Cancer  prevention:  How  to  achieve  widespread  healthy  lifestyle  choices  for
cancer prevention and survival?
As stated  in  the  introduction  most  cancers  in  Europe are  caused by  tobacco,  alcohol
consumption and general  unhealthy  lifestyles;  therefore,  it  is  easy to  hypothesize how
many cancers could be avoided if a healthier lifestyle would be adopted. The quest behind
this mission is not easy to solve however, because making European citizens aware of the
risk associated with certain behaviours and enabling them to live healthier lifestyles is not
so straightforward.  This  working group discussed widely  why people choose unhealthy
lifestyles over healthier alternatives; several discussion points emerged, including the easy
access to cheap unhealthy options compared to good ones, the confusion that arises from
the  available  amount  of,  sometimes  misguiding  and  contradictory,  information,  socio-
economic disparities in different European countries. What is missing to improve cancer
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prevention  in  Europe?  The  working  group  identified  several  potential  action  points,
summarized here below:
1. European science media centre and public engagement program: in order to
fight the spread of medical fake news and the adoption of unhealthy lifestyles we
need to change the way we interact with society; the European Union should invest
money in the creation of a reliable and interactive science media centre (online,
papers, television programs) for its citizens. The communication strategies to be
used  need to  take  inspiration  from the  big  brands,  which  utilize  very  powerful
communication techniques to sell their products; scientists need to team up with
journalists, graphic designers, publicists, movie directors, web influencers so that
each individual group could synergize to communicate our message. We need to
introduce the concept of “pop” science, where correct information is offered in an
appropriate and accessible way. This would promote promotion the idea of RRI
(Responsible Research and Innovation), in which all sorts of different stakeholders,
including citizens, are part of the entire research process This would dramatically
reduce the gap between science and society and reduce significantly the spread of
fake news.  We need to  invest  most  of  our  efforts  in  the  young generations  of
European citizens, to improve their knowledge on cancer prevention.
2. Improvement of current research practice: as basic scientists we recognize that
there is the need to produce more solid data on the effect of unhealthy lifestyles on
cancer; we need to invest more resources in developing more physiological animal
models. We also need to invest more in behavioural/psychological science. Even if
we have some indications of which lifestyle factors increase the risk of cancer we
still do not know that much yet about why people make certain choices, and how
they can be supported to  make healthier  choices.  We need to  invest  in  socio-
economic research studies which could calculate how much money and lives we
could save if  we positively influence the adoption of healthy lifestyles within the
European community.
3. Efficacy of prevention/policy measures: The importance and efficacy of cancer
prevention should be better addressed. Relevant stakeholders and policy makers
should  be  more  actively  involved  in  the  implementation  of  cancer  prevention
measures as there is a need for more funds.
III. Patients: How to evaluate the quality of cancer care that patients and their carers
are receiving across Europe?
One major issue that is of extreme importance and should be taken into consideration is
patient’s  welfare and quality  of  life  from the perspective of  the patient.  Somehow, it  is
imperative not only to focus on cure by itself but also drive our efforts into patient’s care.
Noteworthy, cancer patients are stigmatized in society and for instance, once cured, they
do not get any insurance and/or help to get a job. Therefore, is it enough to focus only on
cancer treatment? One major question that was raised is: how can we evaluate the quality
of cancer care that patients are receiving across Europe?
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Health benefits are usually measured in quality-adjusted life years saved. Cost-usefulness
analysis is widely used to assess the efficacy of different clinical regimens by quantifying
the changes in prognosis (survival rates, time to recurrence, etc.) and corrected by the
quality  of  life.  As  such,  quality  of  life  is  also  a  mean to  address  inequalities  between
patient’s  treatment  and  welfare  worldwide.  Currently,  the  existing  data  systems  are
challenging and EU initiatives, such as European Cancer Information System (European
Commission/JRC. European Network of Cancer Registries: European Cancer Information
System (ECIS)), which is included in the European Network of Cancer Registries (ENCR)
and constitutes a web-based tool that aims to promote awareness on cancer burden and to
report/disseminate cancer burden indicators (incidence, mortality and survival), have a lot
of  space  for  improvement.  Furthermore,  considering  that  this  topic  is  somehow
complicated to evaluate and there is a lot of diversity, it is not totally clear which sources
have  the  most  trustful  information.  Consequently,  getting  the  “right”  indicators  is  key.
Quality of life consists of a very complex and broad issues, including:
• Access  to  a  full  range  of  health  care  professionals  (HCPs;  specialists,  nurses,
psycho-oncologists, etc.) and to treatment innovations;
• Access  of  patients  to  full  information,  allowing  them  to  choose  among  the
therapeutic options;
• Self-care and primary care, along with support from the carers;
• Patient’s safety and how to deal/act in response to therapy adverse effects;
• Follow-up care and survivorship;
• Discrimination against cancer survivors
An important question that was raised by the working group to understand what is currently
missing is: what is patient’s perspective on quality of life? All the parameters related with
quality of life are differently measured across Europe and unfortunately, there are some
 
Figure 4.  
Actions proposed to improve cancer patients care.
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issues that are not well-discussed and measured. Therefore, there is as urgent lack of
agreements/agreed measures/consensus across EU on baseline requirements on quality
of life and data discussion is imperative. Parameters, prioritisation is also pivotal. When
facing cases where it is impossible to address all the parameters, which ones are the most
important?  Data  sources  are  very  heterogenous  across  Europe  and  between  different
sectors (e.g. hospital vs community) and public availability should be revised.
Taking all these into account, the working group proposed several actions that might be
implemented to improve the cancer patients care (Fig. 4).
IV. Low-hanging fruits: How to improve cancer treatment approaches in cancers with
the most urgent needs by 2030?
Although there are several therapeutic approaches currently available for cancer patients,
an important question was raised: how can we improve cancer treatment approaches in
cancers  with  the  most  urgent  needs  by  2030?  To  efficiently  address  this  point,  some
questions were discussed.
• First,  is  it  possible  to  identify  druggable targets? To do that,  it  is  imperative to
perform a better and extensive characterization of cancer types. This will allow the
development of new targeted therapies that might counteract cancer development.
• New therapies  should  be  effective,  safe  (with  the  lowest  side  effects),  allow  a
relatively good quality of life and an easy adhesion to therapeutics. Furthermore,
innovative  formulations  to  reach  an  efficient  delivery  of  the  drugs  should  be
envisioned.
• Facilitate early clinical  trials to evaluate the potential  and efficacy of  these new
molecules/drugs should be considered. Also, to get more accurate results when
evaluating new drugs on trials, patient stratification should be considered to avoid
unnecessary treatments for patients who will probably not respond. On a general
point-of-view, what is missing? The working group identified that the most important
factor that is crucial to improve cancer treatment is to stratify patient populations.
• In addition, it is also important to identify “neglected” cancers. How is this possible?
And should we prioritize some cancers? If so, how can we perform it? According to
which parameters? Should we take into consideration prevalence (rare cancers) or
mortality rates? Or even both? As a direct consequence of this prioritization, moral
and social problems emerge, and it is widely known that the main driver of cancer
therapeutics is currently the available resources (cost-benefit evaluation).
Taking these questions into consideration, the working group proposed some concerted
actions that might be applied in the future to advance these topics:
1. Identify the barriers to treatment, including: Proper identification of the targets;
Optimize  delivery  to  the  target;  Improve  detection  and  diagnosis;  Improve
knowledge transfer;
2. Develop  new  treatment  strategies,  addressing:  Clinical  trial  design  for  less
frequent  cancers  and  rare  targets;  Create  a  database  of  reproducible  failures;
Beating Cancer by 2030: Mission Impossible? 11
Invest  in  new  drugs  that  were  less  explored  by  the  industry;  Exploit  new
combinations of multi-drugs;
3. In  the  testing  of  the  treatments  and in  the  analysis,  we should  consider:
Clinical stratification with regimen; Changes in lifestyle of patients and integration
on the treatments in the patient’s and families’ daily routine;
4. Enable easy knowledge and data sharing at European level:  In this respect,
COST Actions can play a critical role by coordinating joint efforts within and across
the different networks. However, the EU Mission on Cancer will  be critical for a
successful advancement of this action point.
V. Strategy: How can we build a process to crosstalk and coordinate between the
different  stakeholders  (academia,  patients,  industry,  healthcare  providers)  in  the
field of cancer to get the most value for maximising efficacy and beating cancer?
A coordinated and efficient collaboration between the different stakeholders is one of the
most important and determinant factors that might contribute to beat cancer. However, it is
well-known that  these relationships  are  not  easy  and should  be extensively  improved.
Therefore, an important question was raised and discussed: how can we build a process to
cross-talk and coordinate between the different stakeholders (academia, patients, industry,
healthcare  providers)  in  the  field  of  cancer  to  get  the  most  value  and  for  maximizing
efficacy and, therefore, beating cancer? This question has been under debate for many
years  and  has  not  a  simple  question.  Still,  the  working  group  identified  potential  and
important missing facts that should be considered in the future.
Firstly,  the  lack  of  trust  between  the  different  stakeholders  comprises  an  important
drawback  in  this  process.  For  instance,  basic  researchers  usually  do  not  fully  trust
pharmaceutical industries. A problem-solving approach in the development of the research
agenda  as  well  as  creating  specific  and  efficient  cooperation  tools  might  also  help  in
ending this gap and create some cohesion between all the involved entities.
Considering all the bureaucratic paperwork and process in this cross-talk, the development
of a simplifying administrative process for projects under development is urgently needed.
Furthermore, it will be important to include experts and stakeholders in process design with
strategic knowledge that will make this process easier for all involved parties.
Cross-sectional calls should be envisioned that might involve all the stakeholders and be
inter- and trans-disciplinary as much as possible. This may imply that some funding calls
might need to be revised and adapted, which calls also for a change of mindset within the
research and innovation funding agencies.
Last but not the least, academic and research institutions need to adopt a mission-oriented
research. This will facilitate the collaboration and joint efforts with other stakeholders.
The working group highlighted what should be done in the next years to overcome this
problem:
1. Define a clear outcome and timeframe for the cancer mission;
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2. Establishing mechanisms of coordination between the Cancer Mission and Member
States Cancer Plans.
3. Mapping the current state-of-the-art of cancer research and treatment in Europe;
4. Reinforce  current  instruments  for  networking  (research  infrastructures,  COST-
Actions, etc.) to align with the cancer mission for 2030;
5. Introduce innovative funding tools with high levels of plasticity to improve efficiency;
6. Foster or recommend the development of cancer missions-oriented plans between
research and health industries;
7. Create  advisory/dialogue  stakeholders  to  provide  ideas  and  feedback  to  the
mission-control body.
Conclusions
The COST Connect workshop raised important aspects which have to be considered if we
really want to achieve the important goal of beating cancer by 2030. In summary these
below are the main conclusions and recommendations:
Strategy.  We  need  to  connect  all  the  stakeholders  (academia,  patients,  industry,
healthcare providers) and policy makers to build a strong relationship based on trust and
productive cooperation. The main recommendation would be:
• to reinforce current instruments for networking;
• t o introduce innovative funding tools with high level of plasticity to improve
efficiency. 
Education.  We  should  invest  our  time  and  resources  to  prevent  cancer  by  creating
European science media  centres  and public  engagement  programs to  reduce the gap
between science and society and to improve people knowledge on cancer prevention. We
also need to produce more data on the potential positive impact of prevention measures on
the European budgets and better understand the reasons behind unhealthy lifestyles. The
main recommendation would be:
• to create European science media centres;
• to invest money in research to prove the efficacy of prevention measures;
• to invest money in behavioural/psychological science to better understand
why people decide to adopt unhealthy lifestyles. 
Therapy. The translation process of novel cancer targets into the clinic is too inefficient
and expensive, too many clinical trials fail due to poor pre-clinical validation of targets. The
main recommendation would be:
• to invest more resources to develop better pre-clinical cancer models;
• to facilitate early clinical trials and to improve patients’ stratification;
• the initiation of a European Translational Forum (ETF) whose main goal is to
form translational consortia funded by specific translational grants. 
Beating Cancer by 2030: Mission Impossible? 13
Patients. We should not only focus on treatment but also on the quality of life of patients
under  cancer  treatment  and patients  who,  once cured,  are stigmatized in  society.  The
main recommendation would be:
• to  standardize  the  parameters  used  to  assess  the  quality  of  life  across
European countries;
• to create the “European Standards of Cancer care”;
• to improve data source curation and accessibility. 
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